Bradycardia

Veklury® (Remdesivir) Retains Antiviral Activity Against Omicron, Delta and Other Emergent SARS-CoV-2 Variants in Multiple In Vitro Studies

Retrieved on: 
星期五, 二月 11, 2022
Health, Infectious Diseases, Hospitals, Clinical Trials, Pharmaceutical, Biotechnology, Nasdaq, History, Bradycardia, Hypotension, AST, Patient, Rash, Food, ALT, EMS, Risk, Science, Dose, Adolescence, Breathe Me, Human, Research, HIV disease progression rates, Hypoxia, Wheeze, RNA, Death, Shanda, ULN, Anaphylaxis, Fever, ECMO, Kidney failure, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Method, Chloroquine, WA1, Contraindication, FDA, Hypertension, Tachycardia, Angioedema, Perspiration, Allergy, Maintenance, Nausea, Shivering, Disease, Effectiveness, Senior, Delta, Virology, Alpha, Gilead Sciences, Hospital, Diagnosis, Hydroxychloroquine, Severe acute respiratory syndrome coronavirus 2, COVID-19, Hepatitis, Hypersensitivity, EGFR, Pharmaceutical industry, Medical device, Omicron, Remdesivir

The study analyzed in vitro antiviral activity by two methods to understand the susceptibility of ten major SARS-CoV-2 variants to Veklury.

Key Points: 
  • The study analyzed in vitro antiviral activity by two methods to understand the susceptibility of ten major SARS-CoV-2 variants to Veklury.
  • The study results showed similar activity of Veklury against the variants and an early ancestral A lineage isolate detected in Seattle, WA (WA1 strain).
  • Further characterization confirmed that none of the few identified nsp12 mutations prevalent in some of the SARS-CoV-2 variants affects the virus susceptibility to Veklury.
  • Veklury (remdesivir) is a nucleotide analog invented by Gilead, building on more than a decade of the companys antiviral research.

AliveCor Appoints Patricia Baran to Serve as Senior Vice President, Healthcare Americas

Retrieved on: 
星期四, 二月 10, 2022
Chronic care management, Senior, Cardiac cycle, Pharmacy, Multimedia, Ectopia, Teladoc Health, Solution, ReachOut Healthcare America, Leadership, Cardinal Health, Sale, FDA, Technology, Health system, Patient, Deep learning, Employment, ECG, Wage and Hour Division, Compliance, Arrhythmia, Atrial fibrillation, Health, Hospital, GE Healthcare, Stroke, Alivecor, Patty Stonesifer, HIPAA, Medicine, Medical device, Bradycardia, Tachycardia

MOUNTAIN VIEW, Calif., Feb. 10, 2022 /PRNewswire/ -- AliveCor , the leading innovator in FDA-cleared personal electrocardiogram (ECG) technology, today announced the appointment of Patricia Baran as Senior Vice President, Healthcare Americas.

Key Points: 
  • MOUNTAIN VIEW, Calif., Feb. 10, 2022 /PRNewswire/ -- AliveCor , the leading innovator in FDA-cleared personal electrocardiogram (ECG) technology, today announced the appointment of Patricia Baran as Senior Vice President, Healthcare Americas.
  • In this role, Baran will report to Vincent Balsamo , Executive Vice President of Worldwide Sales.
  • Baran will lead the Employer, Payor, and Health System business segments supporting AliveCor's clients and their members with a complete cardiac care management solution.
  • She started her career as a registered nurse and remains a dedicated and passionate advocate for transforming healthcare.

FDA Clears World's First Credit-Card-Sized Personal ECG

Retrieved on: 
星期二, 二月 1, 2022
Hypertension, CEO, Emergency medicine, ECG, Patient, HIPAA, Sale, Water, Atrial fibrillation, Arrhythmia, Systematic review, Face, Stroke, Cardiac cycle, Technology, COVID-19, Alivecor, Deep learning, INT, Public health, Cardiovascular disease, Wireless ambulatory ECG, Compliance, Blood pressure, Smartphone, American Heart Association, Weather, Ectopia, FDA, Ventricular tachycardia, Multimedia, Caregiver, Medical device, Pharmaceutical industry, MD, Bradycardia, Tachycardia, Kardia

MOUNTAIN VIEW, Calif., Feb. 1, 2022 /PRNewswire/ -- AliveCor , the leading innovator in FDA-cleared personal electrocardiogram (ECG) technology, today announced the launch of KardiaMobile Card, the slimmest, most convenient personal ECG device ever created.

Key Points: 
  • MOUNTAIN VIEW, Calif., Feb. 1, 2022 /PRNewswire/ -- AliveCor , the leading innovator in FDA-cleared personal electrocardiogram (ECG) technology, today announced the launch of KardiaMobile Card, the slimmest, most convenient personal ECG device ever created.
  • KardiaMobile Card makes history as the world's first credit-card-sized ECG ever cleared by the FDA.
  • "After disrupting traditional ECG monitoring with our game-changing Kardia platform, we have now achieved the unprecedented milestone of creating the first-ever credit-card-sized personal ECG," said Priya Abani, CEO of AliveCor.
  • KardiaMobile Card pairs with a smartphone using Bluetooth technology to detect six of the most common arrhythmias, more than any other personal ECG on the market.

Innocoll Announces Successful Completion of Debt Refinancing

Retrieved on: 
星期五, 一月 28, 2022
Pharmaceutical, Health, Surgery, Risk, Bradycardia, Paresthesia, Headache, Diffusion, Coma, Anesthetic, Research, Bupivacaine, Shoulder joint, US Foods, City, Injection, Diarrhea, Safety, Seroma, Somnolence, Association, Anemia, Elective surgery, Tremor, Company, Oaktree Capital Management, Investment, Hospital, CNS, Toxicity, Methemoglobinemia, Tinnitus, Oak Tree, Respiratory arrest, Itch, Â, Blurred vision, Hypersensitivity, List of life sciences, GPC, Incidence, Constipation, Industry, FDA, Liver, Northwest Biotherapeutics, Chondrolysis, Blood, Vomiting, Patient, Food, Central nervous system, Allergy, Bruise, Nausea, Dizziness, Hydrogen chloride, Surgeon, C-reactive protein, Dentistry, Medical device, Dietary supplement, Vaccine, Pharmaceutical industry, Dysuria, Fever, Dysgeusia, Hypoesthesia

Aman Kumar, Co-Portfolio Manager of Life Sciences Lending at Oaktree, said, We are pleased to partner with Innocoll at this exciting stage in the companys development.

Key Points: 
  • Aman Kumar, Co-Portfolio Manager of Life Sciences Lending at Oaktree, said, We are pleased to partner with Innocoll at this exciting stage in the companys development.
  • Innocoll Biotherapeutics plc is a global specialty pharmaceutical company headquartered in Athlone, Ireland.
  • Innocoll Biotherapeutics plc and its subsidiaries Innocoll Holdings Limited and Innocoll Pharmaceuticals Limited, are focused on the development and commercialization of pharmaceutical technologies to meet some of todays most important healthcare challenges.
  • Innocoll Biotherapeutics plc is a portfolio business of Gurnet Point Capital.

electroCore, Inc. Announces Three Abstracts to be Presented at International Stroke Conference 2022

Retrieved on: 
星期二, 一月 25, 2022
Safety, Nature, NVN, Overalls, Adult, Migraine, Cluster headache, ElectroCore, COVID-19, Neurology, A luta continua, Nerve conduction study, ECOR, Tachycardia, Indometacin, Private Securities Litigation Reform Act, European, Hypertension, Hemicrania continua, Time, Stroke, Bradycardia, Vagus nerve, United, Skin, Headache, 2021 Essex County Council election, IP, Hearing, Industry, Transcutaneous electrical nerve stimulation, Pain, Patient, Medication overuse headache, American Heart, Hypotension, GLOBE, Conference, Adolescence, FDA, Terminology, Pharmaceutical industry

ROCKAWAY, N.J., Jan. 25, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc.(Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced three abstracts focusing on the possible mechanistic or clinical role of nVNS for the acute treatment of stroke will be presented at the American Heart Associations 2022 International Stroke Conference, February 9th 11th, 2022, in New Orleans, Louisiana.

Key Points: 
  • ROCKAWAY, N.J., Jan. 25, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc.(Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced three abstracts focusing on the possible mechanistic or clinical role of nVNS for the acute treatment of stroke will be presented at the American Heart Associations 2022 International Stroke Conference, February 9th 11th, 2022, in New Orleans, Louisiana.
  • Designed as a portable, easy-to-use technology, gammaCore can be self-administered by patients, as needed, without the potential side effects associated with commonly prescribed drugs.
  • When placed on a patients neck over the vagus nerve, gammaCore stimulates the nerves afferent fibers, which may lead to a reduction of pain in patients.
  • Actual results could differ from those projected in any forward-looking statements due to numerous factors.

National Headache Foundation Position Statement on the Treatment of Migraine

Retrieved on: 
星期三, 一月 19, 2022
Disability, Education, Awareness, Research, Patient, Vertigo, HCU, Dizziness, Phonophobia, Standing, Migraine, Human, Population, Contraindication, NHF, Nausea, ER, Neutralizing antibody, Weight gain, Disease, Tolerability, GLOBE, Language, Positive statement, Headache, Goal, Tremor, Pain, Heart, Tinnitus, Work, Bradycardia, Risk, CGRP, Topiramate, FDA, Chronic kidney disease, Practitioner, Vomiting, Photophobia, Pharmaceutical industry, Health insurance, Medicine, Risk management, Residential care

Chicago, IL, Jan. 19, 2022 (GLOBE NEWSWIRE) -- For more than 50 years, the National Headache Foundation (NHF) has been the voice for more than 40 million American adults with migraine.

Key Points: 
  • Chicago, IL, Jan. 19, 2022 (GLOBE NEWSWIRE) -- For more than 50 years, the National Headache Foundation (NHF) has been the voice for more than 40 million American adults with migraine.
  • Unfortunately, the current care models adopted by payers (health insurance) have not kept pace with the many advances in treatment.
  • The vision of the National Headache Foundation (NHF) is a world without headache.
  • In the future, NHF will expand upon this Position Statement and propose specific treatment guidelines.

SHAREHOLDER ALERT FILING DEADLINE TODAY: Pomerantz Law Firm Announces Reminds Shareholders with Losses on their Investment in Owlet, Inc. f/k/a Sandbridge Acquisition Corporation and Certain Officers – OWLT; OWLT WS; SBG

Retrieved on: 
星期二, 一月 18, 2022
Securities Exchange Act of 1934, Desaturation, SBG, News, Person, Pomerantz, Business architecture, Regulation of tobacco by the U.S. Food and Drug Administration, NYSE, Ext, Company, LLP, GLOBE, Lists of action films, Court, Health, Central District, Parent, Marketing, Lists of schools in England, OWLT, Complaint, Bradycardia, Food, FDA, Heart rate, Defendant, District court, Acquisition, Online gambling, Owlet

NEW YORK, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Owlet, Inc. (Owlet or the Company) f/k/a Sandbridge Acquisition Corporation (Sandbridge) (NYSE: OWLT; OWLT WS; SBG) and certain of its officers.

Key Points: 
  • NEW YORK, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Owlet, Inc. (Owlet or the Company) f/k/a Sandbridge Acquisition Corporation (Sandbridge) (NYSE: OWLT; OWLT WS; SBG) and certain of its officers.
  • Plaintiff pursues claims against the Defendants under the Securities Exchange Act of 1934 (the Exchange Act).
  • To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

Final Deadline Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Lead Plaintiff Deadline in Securities Fraud Class Action Lawsuit Filed Against Owlet, Inc. (OWLT)

Retrieved on: 
星期一, 一月 17, 2022
Desaturation, SBG, Federal, News, Smart, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Infant, NYSE, LLP, GLOBE, Oxygen, Cosmetic, Central District, Federal Food, Drug, and Cosmetic Act, Parent, Marketing, OWLT, Bradycardia, Letter, FDA, Fraud, District court, Lead, Private investigator, Architecture, Food, Owlet

Kessler Topaz Meltzer & Check, LLP encourages Owlet investors who have suffered significant losses to contact the firm directly to acquire more information.

Key Points: 
  • Kessler Topaz Meltzer & Check, LLP encourages Owlet investors who have suffered significant losses to contact the firm directly to acquire more information.
  • The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel.
  • ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP
    Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country and around the world.
  • The complaint in this action was not filed by Kessler Topaz Meltzer & Check, LLP.

OWLET DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Owlet, Inc. and Encourages Investors to Contact the Firm

Retrieved on: 
星期一, 一月 17, 2022
Legal, Professional Services, Desaturation, Telephone, Jeanne Eagels, News, Person, Business architecture, Regulation of tobacco by the U.S. Food and Drug Administration, NYSE, Court, Health, Central District, Parent, Marketing, Lists of schools in England, OWLT, Company, Advertising, Bradycardia, Food, P.C, FDA, Defendant, District court, Owlet

Investors have until January 18, 2022 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until January 18, 2022 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • On October 4, 2021, Owlet revealed that it had received a warning letter from the U.S. Food and Drug Administration (FDA), which stated that the Companys marketing of its Owlet Smart Sock product .
  • is a nationally recognized law firm with offices in New York, California, and South Carolina.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

Lead Plaintiff Deadline Approaching: Kessler Topaz Meltzer & Check, LLP Announces Deadline in Securities Fraud Class Action Lawsuit Filed Against Owlet, Inc.  

Retrieved on: 
星期五, 一月 14, 2022
Legal, Professional Services, Desaturation, SBG, Federal, News, Smart, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Infant, NYSE, LLP, Oxygen, Cosmetic, Federal Food, Drug, and Cosmetic Act, Parent, Marketing, OWLT, Bradycardia, Letter, FDA, Fraud, Lead, Private investigator, Food, Owlet

The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that a securities class action lawsuit has been filed against Owlet, Inc. (Owlet) ( NYSE: OWLT ) f/k/a Sandbridge Acquisition Corp. (NYSE: SBG) (Sandbridge).

Key Points: 
  • The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that a securities class action lawsuit has been filed against Owlet, Inc. (Owlet) ( NYSE: OWLT ) f/k/a Sandbridge Acquisition Corp. (NYSE: SBG) (Sandbridge).
  • The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel.
  • ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP
    Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country and around the world.
  • The complaint in this action was not filed by Kessler Topaz Meltzer & Check, LLP.